Ishita Drugs Reports Highest Operating Profit in Five Quarters, Evaluation Adjusted to 1
Ishita Drugs & Industries has announced its financial results for the quarter ending December 2024, revealing the highest operating profit in five quarters at Rs 0.30 crore. Despite a flat overall performance, recent evaluations indicate a shift in the assessment of the company's financial health within the pharmaceuticals sector.
Ishita Drugs & Industries, a microcap player in the Pharmaceuticals & Drugs sector, has recently reported its financial results for the quarter ending December 2024. The results, announced on February 13, 2025, indicate a notable development in the company's evaluation. The score has seen an adjustment, moving from 0 to 1 over the past three months.The financial data reveals that Ishita Drugs achieved its highest operating profit (PBDIT) in the last five quarters, reaching Rs 0.30 crore. This upward trend in operating profit suggests a positive trajectory in the company's near-term performance.
While the overall financial performance for the quarter has been characterized as flat, the recent changes in evaluation reflect a shift in the assessment of the company's financial health. Investors and stakeholders may find these developments noteworthy as they consider the company's position within the pharmaceuticals industry.
For more insights on Ishita Drugs & Industries and to stay updated on its financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
